Cephalon Pursues Gambit In Oncology Through Ambit Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
Access to Ambit's kinase profiling technology could spur development of oncology pipeline.
You may also be interested in...
Cephalon’s Oncologic Treanda On Track For Q4 NDA Filing
Firm's initial goal is non-Hodgkin's lymphoma, but plans are in place for studies in chronic lymphocytic leukemia, mantle cell lymphoma and small-cell lung.
Cephalon’s Oncologic Treanda On Track For Q4 NDA Filing
Firm's initial goal is non-Hodgkin's lymphoma, but plans are in place for studies in chronic lymphocytic leukemia, mantle cell lymphoma and small-cell lung.
Cephalon To Develop Oncology Franchise Following Acquisition Of CTI’s Trisenox
Cephalon will build a hematology franchise around the Trisenox acquisition; the company may add its Phase II tyrosine kinase inhibitor (CEP-701) and Salmedix’ lymphoma treatment Treanda when that acqusition closes. CTI is selling Trisenox to reinvest in its late-stage pipeline.